Carbon Nanotube‐Based Biosensor
Source abstract
Abstract
Carbon nanotubes, compounded into plastic to create bulk electrodes, form the basis of a novel sensor for biological assays. The nanotubes function as both a solid phase and working electrode for generation of electrochemiluminescence, the detection method used in this system. The Figure shows a scanning electron microscopy image of a composite used for an immunoassay. The bright spots in the image are 10 nm diameter gold colloids covalently attached to antibodies. The inset shows a region of a composite with no gold colloids.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Advanced biosensing and bioanalysis techniques · Carbon Nanotubes in Composites
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (42)
Show source-provided references
1. H. G. Tennant US Patent 4 663 230 1987.
2. 10.1038/354056a010.1038/354056a0 ↗
3. 10.1021/cr970102g10.1021/cr970102g ↗
4. 10.1126/science.272.5261.52310.1126/science.272.5261.523 ↗
5. 10.1126/science.277.5334.197110.1126/science.277.5334.1971 ↗
6. 10.1021/ja992945q10.1021/ja992945q ↗
7. 10.1126/science.273.5274.48310.1126/science.273.5274.483 ↗
8. 10.1126/science.283.5401.51210.1126/science.283.5401.512 ↗
9. 10.1063/1.11856810.1063/1.118568 ↗
10. 10.1002/adma.1997009012210.1002/adma.19970090122 ↗
11. 10.1126/science.284.5418.134010.1126/science.284.5418.1340 ↗
12. 10.1126/science.286.5447.214810.1126/science.286.5447.2148 ↗
13. 10.1126/science.287.5453.62210.1126/science.287.5453.622 ↗
14. 10.1002/1521-4095(20020304)14:5<382::AID-ADMA382>3.0.CO;2-Y10.1002/1521-4095(20020304)14:5<382::AID-ADMA382>3.0.CO;2-Y ↗
15. 10.1016/S0009-2614(01)00159-210.1016/S0009-2614(01)00159-2 ↗
16. 10.1016/S0079-6107(01)00011-610.1016/S0079-6107(01)00011-6 ↗
17. 10.1149/1.208617110.1149/1.2086171 ↗
18. A. J. Bard J. D. Debad J. K. Leland G. B. Sigal J. L. Wilbur J. N. Wohlstadter inEncyclopedia of Analytical Chemistry(Ed: R. A. Meyers) John Wiley and Sons Chichester UK2000 pp. 9842–9849.
19. 10.1021/ja990001v10.1021/ja990001v ↗
20. 10.1002/(SICI)1521-4095(199902)11:2<154::AID-ADMA154>3.0.CO;2-B10.1002/(SICI)1521-4095(199902)11:2<154::AID-ADMA154>3.0.CO;2-B ↗
21. 10.1016/S0022-0728(97)80067-810.1016/S0022-0728(97)80067-8 ↗
22. Bening R.C. · Polym. Prepr. (Am. Chem. Soc. Div. Polym. Chem.) · 1990 · 30 · 420
23. 10.1002/adma.1996008021210.1002/adma.19960080212 ↗
24. 10.1002/(SICI)1099-1352(199634/12)9:5/6<383::AID-JMR269>3.0.CO;2-Z10.1002/(SICI)1099-1352(199634/12)9:5/6<383::AID-JMR269>3.0.CO;2-Z ↗
25. 10.1038/2787310.1038/27873 ↗
26. 10.1002/(SICI)1521-3773(19990712)38:13/14<1912::AID-ANIE1912>3.0.CO;2-210.1002/(SICI)1521-3773(19990712)38:13/14<1912::AID-ANIE1912>3.0.CO;2-2 ↗
27. 10.1021/nl010095i10.1021/nl010095i ↗
28. 10.1021/ja010172b10.1021/ja010172b ↗
29. 10.1002/(SICI)1521-4095(199806)10:9<701::AID-ADMA701>3.0.CO;2-410.1002/(SICI)1521-4095(199806)10:9<701::AID-ADMA701>3.0.CO;2-4 ↗
30. 10.1016/S0020-1693(97)05926-410.1016/S0020-1693(97)05926-4 ↗
31. Bulk resistivity (27 wt.‐% nanotubes 4‐point probe) was ∼ 0.3 Ω cm. We measured the double‐layer capacitance (Cdl) of extruded nanotube–EVA sheets before (4 μF cm–2) and after (100–200 μF cm–2) treatment with chromic/sulfuric acid. We attributed the increased capacitance to increased surface area of exposed nanotubes. For reference Cdlof a 4 μm thick filtered cake of pure nanotubes (no polymer) was 300 μF cm–2.
32. Nanotubes provided by Hyperion Catalysis Incorporated (Hyperion Fibrils CC grade). We blended 270 g of carbon nanotubes and 730 g of EVA (Quantum Microthene FE530) in a lab mixer. The nanotube–EVA blend was compounded pelletized and extruded (Brabender PL2000 Plasti‐Corder) to produce a continuous ribbon (∼ 15 cm wide ∼ 1 mm thick) of nanotube–EVA composite.
33. SEM images of fractured samples indicated that the layer was at least 50 nm thick.
34. Oxidation of nanotubes [22 23] generates oxygen‐containing functional groups. We do not know the composition of these functional groups. Based on our ability to conductN‐hydroxysuccinimide (NHS)–ester couplings to the surface (Scheme 1) we hypothesized that carboxylic acid groups were present. FTIR showed no measurable signal for carbonyls. Since EVA contains oxygen we were unable to use X‐ray photon spectroscopy (XPS) to measure additional oxygen introduced by oxidation of the surface.
35. The majority of the streptavidin was covalently coupled. Composites that were oxidized and activated with NHS–esters bound three times as much streptavidin as did composites that were oxidized but not NHS–ester activated.
36. A two‐dimensional protein crystal of streptavidin (effectively a close‐packed monolayer of streptavidin) has 2.3 pmol streptavidin per square centimeter. We calculated this number from experimental data in reference [36].
37. 10.1016/S0006-3495(98)77973-110.1016/S0006-3495(98)77973-1 ↗
38. Antibodies directed against AFP were adsorbed on 10 nm diameter gold colloids (Sigma). Binding assays were conducted as described for ECL‐based assays except that the solution of the antibody labeled with Ru(bpy)32+was replaced with the suspension of the antibody adsorbed on colloidal gold.
39. We used a home‐made electrochemiluminescence cell for ECL measurements. The nanotube–EVA composite was the working electrode; a ring of Pt mesh was the counter electrode. The reference electrode was Ag/AgCl. ECL emissions were measured with a photomultiplier tube through an optical aperature in the cell. The current and potential were controlled with a potentiostat external to the cell. The electrodes were placed in the electrochemiluminescence cell and the cell was flushed with a buffered solution of tripropylamine (ECL Assay Buffer IGEN International Inc.). The potential at the working electrode was held at 0.0 V for 100 s ramped to –0.8 V at 100 mV s–1 then ramped to 2.3 V at 100 mV s–1. A plot of the ECL signal from the bound label versus potential showed a peak at approximately 1.1 V. We report the total integrated current measured at the luminometer.
40. In normal pregnancies maternal serum AFP is first detectable (∼ 5 ng mL–1 ∼ 0.1 nM) at ∼ 12 weeks gestation and reaches its maximum (∼ 250 ng mL–1 ∼ 3.6 nM) at about 25 weeks. Levels of AFP in amniotic fluid can be several orders of magnitude larger (∼ 20 ug mL–1 ∼ 290 nM). See [40].
41. C. A. Burtis E. R. Ashwood Tietz Textbook of Clinical Chemistry 2nd ed. W. B. Saunders Philadelphia PA1994.
42. 10.1149/1.208617110.1149/1.2086171 ↗